Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6280641 | Neuroscience Letters | 2015 | 21 Pages |
Abstract
Bdnf promoter methylation levels did not differ between AD patients and controls. Similarly, Sirt1 promoter revealed minimal levels of methylation which did not display significant differences between groups. No significant difference was revealed between AD patients and controls also in Psen1 methylation, showing a large variability of values among subjects. Although peripheral Bdnf expression is associated with differential promoter methylation in psychiatric and neurological disorders, our results suggest that different mechanisms take place in AD. The finding that the control of Sirt1 protein levels in blood is not exerted through the repression of mRNA expression by promoter hypermethylation is in agreement with previous data. In contrast, other studies reported that Psen1 methylation may be increased or decreased in AD patients, suggesting that additional studies are required. In conclusion, this study shows that peripheral levels of the potential AD biomarker proteins Bdnf, Sirt1, and Psen1 are not regulated by different promoter methylation.
Keywords
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Lucia Carboni, Francesca Lattanzio, Sanzio Candeletti, Elisa Porcellini, Elena Raschi, Federico Licastro, Patrizia Romualdi,